PMID- 33113620
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210108
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 42
IP  - 10
DP  - 2020 Oct 23
TI  - [Expert consensus on the management of adverse events of ErbB family tyrosine 
      kinase inhibitors in breast cancer].
PG  - 798-806
LID - 10.3760/cma.j.cn112152-20200805-00711 [doi]
AB  - Human epidermal growth factor receptor-2 (HER-2) tyrosine kinase inhibitors (TKI) 
      is the targeted drug of HER-2-positive breast cancer. Lapatinib, pyrotinib and 
      neratinib, as ErbB family TKIs, have been approved by National Medical Products 
      Administration and applied in the treatment of HER-2 positive breast cancer in 
      China. The most common adverse effects (AEs) of TKI agents include diarrhea, 
      drug-induced liver injury (DILI), nausea, vomiting, skin toxicity, cardiotoxicity 
      and oral mucositis. The Breast Cancer Expert Group of Chinese Society of Clinical 
      Oncology (CSCO) summarized the incidence and characteristics of AEs of TKI, 
      evaluated the manifestations and severity of AEs, and formulated the consensus of 
      the management of common AEs based on the clinical experiences and updated 
      advances from domestic and abroad studies. This consensus aims to provide the 
      practical strategy for clinicians in the management of ErbB-family TKI-related 
      AEs in China, and eventually enhance the patients' compliance and improve the 
      therapeutic efficacy.
FAU - Wang, B Y
AU  - Wang BY
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 
      Medical College, Fudan University, Shanghai 200032, China.
FAU - Ge, R
AU  - Ge R
AD  - Department of General Surgery, Huadong Hospital Affiliated to Fudan University, 
      Shanghai 200040, China.
FAU - Jiang, Z F
AU  - Jiang ZF
AD  - Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General 
      Hospital, Beijing 100071, China.
CN  - Breast Cancer Expert Group of Chinese Society of Clinical Oncology
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - *Breast Neoplasms/drug therapy
MH  - China
MH  - Consensus
MH  - Female
MH  - Humans
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Receptor, ErbB-2/*antagonists & inhibitors
OTO - NOTNLM
OT  - Adverse event
OT  - Breast neoplasms
OT  - Expert consensus
OT  - Human epidermal growth factor receptor 2
OT  - Tyrosine kinase inhibitors
EDAT- 2020/10/29 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/10/28 23:15
PHST- 2020/10/28 23:15 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
AID - 10.3760/cma.j.cn112152-20200805-00711 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2020 Oct 23;42(10):798-806. doi: 
      10.3760/cma.j.cn112152-20200805-00711.